Endpoints News

LGBTQ+ Leaders in Biopharma nominations are open		Read in browser

Thank you for reading, dupa dupackia!

basic

UPGRADE

M Tue W Th F

3 March, 2026

AI-driven drug discovery is already reshaping pipelines. But algorithms alone won’t get a drug to the clinic. Join us for a free virtual program — then continue the conversation at an in-person only fireside chat and happy hour in Boston. Reserve your spot.

presented by

The $50K-a-day problem in clinical trial enrollment

SPOTLIGHT

Who’s leading LGBTQ+ inclusion in biopharma? Nominate them for Endpoints’ annual report

news

Esperion to buy Corstasis and its nasal spray for edema for $75M upfront

Updated: Caught in FDA's rare disease crackdown, uniQure seeks ethical path forward for Huntington's treatment

United Therapeutics to take pulmonary hypertension drug to FDA for approval

Mar 03

12:00 pm ET

Innovation in biopharmaceuticals: A conversation with Fujifilm leaders

in case you missed it

Roche gets third pivotal win with MS drug, but liver signal could be a problem

Bavarian Nordic CEO Paul Chaplin exits, months after failed $3B takeover

Two new ACIP members added as vaccine injury-focused meeting looms

News Briefing

Aardvark's stock plummets on study pause; BioNTech heads to Phase 3 with DualityBio ADC

FDA lifts hold on second Intellia Phase 3 gene editing trial

Candid to go public via reverse merger with Rallybio

Phase 3 China obesity biotech gets $72M, including support from OrbiMed

Pfizer CEO flags concerns with US FDA's vaccine leadership

How Genentech uncovered an alleged scheme to ship an expensive drug into the U.S. from Canada

San Francisco Business Times

All eyes were on uniQure yesterday, when it announced the FDA had recommended a sham-controlled study of its Huntington's disease therapy to be reviewed for approval. Max Gelman was on the story throughout the day, with a comprehensive look at the back-and-forth between uniQure and the agency.